Adding Inspra(R) (Eplerenone) To Standard Therapy Reduces The Incidence Of New Onset AF/F In Patients With Systolic Heart Failure, Sub-Analysis Shows
Links shared publicly online about this topic.
- 272total visits
Adding Inspra(R) (Eplerenone) To Standard Therapy Reduces The Incidence Of New Onset AF/F In Patients With Systolic Heart Failure, Sub-Analysis Shows
Pfizer Inc. (NYSE: PFE) today announced results from a pre-specified sub-analysis1 of the EMPHASIS-HF trial2 which showed that Inspra® (eplerenone), added to standard recommended therapy, stat
View full resource at medicalnewstoday.com
Tags: Heart, Heart Disease, Heart Failure, Pfizer
Most Recently Shared on May 23, 2011 at 1:35 pm By:
MedicalNewsToday: Adding Inspra(R) (Eplerenone) To Standard Therapy Reduces The Incidence: http://bit.ly/iKgRZu Full http://bit.ly/ixPhra
Also Shared By:
Advertisement
MNT Cardiovascular
@mnt_cardiovasc
Adding Inspra(R) (Eplerenone) To Standard Therapy Reduces The Incidence Of New Onset AF/F In Patients With Systolic He... http://mnt.to/3WcC
1 year ago...